Literature DB >> 25561469

Characterization of human cyclin-dependent kinase 12 (CDK12) and CDK13 complexes in C-terminal domain phosphorylation, gene transcription, and RNA processing.

Kaiwei Liang1, Xin Gao1, Joshua M Gilmore1, Laurence Florens1, Michael P Washburn2, Edwin Smith3, Ali Shilatifard4.   

Abstract

Cyclin-dependent kinase 9 (CDK9) and CDK12 have each been demonstrated to phosphorylate the RNA polymerase II C-terminal domain (CTD) at serine 2 of the heptad repeat, both in vitro and in vivo. CDK9, as part of P-TEFb and the super elongation complex (SEC), is by far the best characterized of CDK9, CDK12, and CDK13. We employed both in vitro and in vivo assays to further investigate the molecular properties of CDK12 and its paralog CDK13. We isolated Flag-tagged CDK12 and CDK13 and found that they associate with numerous RNA processing factors. Although knockdown of CDK12, CDK13, or their cyclin partner CCNK did not affect the bulk CTD phosphorylation levels in HCT116 cells, transcriptome sequencing (RNA-seq) analysis revealed that CDK12 and CDK13 losses in HCT116 cells preferentially affect expression of DNA damage response and snoRNA genes, respectively. CDK12 and CDK13 depletion also leads to a loss of expression of RNA processing factors and to defects in RNA processing. These findings suggest that in addition to implementing CTD phosphorylation, CDK12 and CDK13 may affect RNA processing through direct physical interactions with RNA processing factors and by regulating their expression.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25561469      PMCID: PMC4333096          DOI: 10.1128/MCB.01426-14

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  45 in total

1.  Phosphorylation of RNA polymerase II is independent of P-TEFb in the C. elegans germline.

Authors:  Elizabeth Anne Bowman; Christopher Ray Bowman; Jeong H Ahn; William G Kelly
Journal:  Development       Date:  2013-07-31       Impact factor: 6.868

2.  The regulation of glial-specific splicing of Neurexin IV requires HOW and Cdk12 activity.

Authors:  Floriano Rodrigues; Leila Thuma; Christian Klämbt
Journal:  Development       Date:  2012-03-29       Impact factor: 6.868

3.  DSIF, a novel transcription elongation factor that regulates RNA polymerase II processivity, is composed of human Spt4 and Spt5 homologs.

Authors:  T Wada; T Takagi; Y Yamaguchi; A Ferdous; T Imai; S Hirose; S Sugimoto; K Yano; G A Hartzog; F Winston; S Buratowski; H Handa
Journal:  Genes Dev       Date:  1998-02-01       Impact factor: 11.361

Review 4.  Progression through the RNA polymerase II CTD cycle.

Authors:  Stephen Buratowski
Journal:  Mol Cell       Date:  2009-11-25       Impact factor: 17.970

5.  Interaction of cyclin-dependent kinase 12/CrkRS with cyclin K1 is required for the phosphorylation of the C-terminal domain of RNA polymerase II.

Authors:  S-W Grace Cheng; Michael A Kuzyk; Annie Moradian; Taka-Aki Ichu; Vicky C-D Chang; Jerry F Tien; Sarah E Vollett; Malachi Griffith; Marco A Marra; Gregg B Morin
Journal:  Mol Cell Biol       Date:  2012-09-17       Impact factor: 4.272

6.  The C-terminal domain of RNA polymerase II is modified by site-specific methylation.

Authors:  Robert J Sims; Luis Alejandro Rojas; David B Beck; Roberto Bonasio; Roland Schüller; William J Drury; Dirk Eick; Danny Reinberg
Journal:  Science       Date:  2011-04-01       Impact factor: 47.728

7.  CrkRS: a novel conserved Cdc2-related protein kinase that colocalises with SC35 speckles.

Authors:  T K Ko; E Kelly; J Pines
Journal:  J Cell Sci       Date:  2001-07       Impact factor: 5.285

8.  The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes.

Authors:  Dalibor Blazek; Jiri Kohoutek; Koen Bartholomeeusen; Eric Johansen; Petra Hulinkova; Zeping Luo; Peter Cimermancic; Jernej Ule; B Matija Peterlin
Journal:  Genes Dev       Date:  2011-10-15       Impact factor: 11.361

9.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data.

Authors:  Mark D Robinson; Davis J McCarthy; Gordon K Smyth
Journal:  Bioinformatics       Date:  2009-11-11       Impact factor: 6.937

10.  3' end formation of pre-mRNA and phosphorylation of Ser2 on the RNA polymerase II CTD are reciprocally coupled in human cells.

Authors:  Lee Davidson; Lisa Muniz; Steven West
Journal:  Genes Dev       Date:  2014-01-29       Impact factor: 11.361

View more
  73 in total

Review 1.  Molecular mechanisms of HIV latency.

Authors:  Daniele C Cary; Koh Fujinaga; B Matija Peterlin
Journal:  J Clin Invest       Date:  2016-01-05       Impact factor: 14.808

Review 2.  Super-Enhancer-Driven Transcriptional Dependencies in Cancer.

Authors:  Satyaki Sengupta; Rani E George
Journal:  Trends Cancer       Date:  2017-04-12

3.  BRCA1 Deficiency Upregulates NNMT, Which Reprograms Metabolism and Sensitizes Ovarian Cancer Cells to Mitochondrial Metabolic Targeting Agents.

Authors:  Arun Kanakkanthara; Kiran Kurmi; Thomas L Ekstrom; Xiaonan Hou; Emma R Purfeerst; Ethan P Heinzen; Cristina Correia; Catherine J Huntoon; Daniel O'Brien; Andrea E Wahner Hendrickson; Sean C Dowdy; Hu Li; Ann L Oberg; Taro Hitosugi; Scott H Kaufmann; S John Weroha; Larry M Karnitz
Journal:  Cancer Res       Date:  2019-10-16       Impact factor: 12.701

4.  Engineering an analog-sensitive CDK12 cell line using CRISPR/Cas.

Authors:  Bartlomiej Bartkowiak; Christopher Yan; Arno L Greenleaf
Journal:  Biochim Biophys Acta       Date:  2015-07-17

5.  Therapeutic Targeting of MLL Degradation Pathways in MLL-Rearranged Leukemia.

Authors:  Kaiwei Liang; Andrew G Volk; Jeffrey S Haug; Stacy A Marshall; Ashley R Woodfin; Elizabeth T Bartom; Joshua M Gilmore; Laurence Florens; Michael P Washburn; Kelly D Sullivan; Joaquin M Espinosa; Joseph Cannova; Jiwang Zhang; Edwin R Smith; John D Crispino; Ali Shilatifard
Journal:  Cell       Date:  2017-01-05       Impact factor: 41.582

Review 6.  The pol II CTD: new twists in the tail.

Authors:  Justyna Zaborowska; Sylvain Egloff; Shona Murphy
Journal:  Nat Struct Mol Biol       Date:  2016-09-06       Impact factor: 15.369

Review 7.  Kinase inhibitors: the road ahead.

Authors:  Fleur M Ferguson; Nathanael S Gray
Journal:  Nat Rev Drug Discov       Date:  2018-03-16       Impact factor: 84.694

8.  Sensitizing HR-proficient cancers to PARP inhibitors.

Authors:  Elgene Lim; Shawn F Johnson; Matthias Geyer; Violeta Serra; Geoffrey I Shapiro
Journal:  Mol Cell Oncol       Date:  2017-03-03

Review 9.  Human CDK12 and CDK13, multi-tasking CTD kinases for the new millenium.

Authors:  Arno L Greenleaf
Journal:  Transcription       Date:  2018-10-22

10.  Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors.

Authors:  Tinghu Zhang; Nicholas Kwiatkowski; Calla M Olson; Sarah E Dixon-Clarke; Brian J Abraham; Ann K Greifenberg; Scott B Ficarro; Jonathan M Elkins; Yanke Liang; Nancy M Hannett; Theresa Manz; Mingfeng Hao; Bartlomiej Bartkowiak; Arno L Greenleaf; Jarrod A Marto; Matthias Geyer; Alex N Bullock; Richard A Young; Nathanael S Gray
Journal:  Nat Chem Biol       Date:  2016-08-29       Impact factor: 15.040

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.